SG10201913987UA - PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - Google Patents

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Info

Publication number: SG10201913987UA
Authority: SG; Singapore
Prior art keywords: pyrazin; pyrrolo; imidazo; trifluoroethyl; carboxamide
Prior art date: 2015-10-16

Application number

SG10201913987UA

Inventor

Ayman D Allian

Jayanthy Jayanth

Mohamed-Eslam F Mohamed

Mathew M Mulhern

Fredrik Lars Nordstrom

Ahmed A Othman

Michael J Rozema

Lakshmi Bhagavatula

Patrick J Marroum

Peter T Mayer

Ahmad Y Sheikh

Thomas B Borchardt

KLÜNDER Ben

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-16

Filing date

2016-10-17

Publication date

2020-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57209916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913987U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-17 Application filed by Abbvie Inc filed Critical Abbvie Inc

2020-03-30 Publication of SG10201913987UA publication Critical patent/SG10201913987UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Catalysts (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

SG10201913987UA 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF SG10201913987UA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201562242797P	2015-10-16	2015-10-16
US201562267672P	2015-12-15	2015-12-15
US201662301537P	2016-02-29	2016-02-29
US201662352380P	2016-06-20	2016-06-20

Publications (1)

Publication Number	Publication Date
SG10201913987UA true SG10201913987UA (en)	2020-03-30

Family

ID=57209916

Family Applications (8)

Application Number	Title	Priority Date	Filing Date
SG10201913990RA SG10201913990RA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG11201802990RA SG11201802990RA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913989QA SG10201913989QA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913993QA SG10201913993QA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913997WA SG10201913997WA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913999PA SG10201913999PA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913986YA SG10201913986YA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913987UA SG10201913987UA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Family Applications Before (7)

Application Number	Title	Priority Date	Filing Date
SG10201913990RA SG10201913990RA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG11201802990RA SG11201802990RA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913989QA SG10201913989QA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913993QA SG10201913993QA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913997WA SG10201913997WA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913999PA SG10201913999PA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
SG10201913986YA SG10201913986YA (en)	2015-10-16	2016-10-17	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Country Status (13)

Country	Link
US (39)	US20170129902A1 (en)
EP (3)	EP4647129A2 (en)
JP (7)	JP6770775B2 (en)
KR (2)	KR102753815B1 (en)
CN (7)	CN120289468A (en)
AU (5)	AU2016340167B2 (en)
BR (1)	BR122022024925B1 (en)
CA (8)	CA3123260C (en)
IL (3)	IL314468A (en)
MX (2)	MX387822B (en)
RU (1)	RU2018117889A (en)
SG (8)	SG10201913990RA (en)
WO (1)	WO2017066775A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2836833A1 (en)	1978-08-23	1980-04-10	Volkswagenwerk Ag	INTERNAL COMBUSTION ENGINE WITH CYLINDERS IN TWO ROWS
PL2506716T3 (en)	2009-12-01	2017-10-31	Abbvie Inc	Novel tricyclic compounds
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) *	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20170129902A1 (en)	2015-10-16	2017-05-11	Abbvie Inc.	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN110392572A (en)	2017-03-09	2019-10-29	艾伯维公司	Treatments for Crohn's disease and ulcerative colitis
US11564922B2 (en)	2017-03-09	2023-01-31	Abbvie Inc.	Methods of treating crohn's disease and ulcerative colitis
WO2019016745A1 (en) *	2017-07-19	2019-01-24	Dr. Reddy's Laboratories Limited	Alternate processes for the preparation of pyrrolidine derivatives
SMT202400306T1 (en)	2018-03-30	2024-09-16	Incyte Corp	Treatment of hidradenitis suppurativa using jak inhibitors
CN110872250B (en) *	2018-08-31	2023-01-10	苏州鹏旭医药科技有限公司	Two compounds, preparation methods thereof and application thereof in synthesis of ursitinib
ES2997858T3 (en)	2018-08-31	2025-02-18	Suzhou Pengxu Pharmatech Co Ltd	Synthesis methods for upadacitinib and intermediate thereof
WO2020063939A1 (en) *	2018-09-29	2020-04-02	苏州科睿思制药有限公司	Crystal form of upadacitinib and preparation method and use thereof
CN111217819B (en) *	2018-11-27	2021-05-14	杭州科巢生物科技有限公司	Synthetic method of sepiatinib
EP3891151A1 (en)	2018-12-05	2021-10-13	LEK Pharmaceuticals d.d.	Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN109369659B (en) *	2018-12-06	2020-10-27	浙江师范大学	Synthetic method of JAK inhibitor
WO2020115213A1 (en)	2018-12-07	2020-06-11	Lek Pharmaceuticals D.D.	Solvate of a selective jak1 inhibitor
CN109705011B (en) *	2019-01-18	2021-02-19	浙江师范大学	A kind of synthetic method and intermediate of Upatinib intermediate
US20210380596A1 (en) *	2019-03-01	2021-12-09	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Upadacitinib crystal form and preparation method therefor and use thereof
WO2020202183A1 (en)	2019-03-29	2020-10-08	Mylan Laboratories Limited	The process for the preparation of upadacitinib and its intermediates
CN111909160B (en)	2019-05-09	2024-05-28	苏州鹏旭医药科技有限公司	Martinib salt compound and preparation method thereof
CN110229160A (en) *	2019-06-11	2019-09-13	南京新酶合医药科技有限公司	The preparation method of (5- tosyl -5H- pyrrolo- [2,3-b] pyrazine -2- base) urethanes
CN110117245B (en) *	2019-06-21	2021-03-02	浙江师范大学	Synthetic method of JAK inhibitor intermediate
WO2021005484A1 (en) *	2019-07-11	2021-01-14	Mankind Pharma Ltd.	Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
CN110615753A (en) *	2019-09-02	2019-12-27	南京新酶合医药科技有限公司	Synthesis method of (3R,4S) -1-substituted-4-ethylpyrrole-3-carboxylic acid
CN118986985A (en) *	2019-09-30	2024-11-22	艾伯维公司	Upadacitinib for the treatment of spondyloarthritis and psoriasis
CN111072543B (en) *	2019-11-13	2021-06-04	北京海美桐医药科技有限公司	Preparation method and application of (3R,4S) -4-ethylpyrrolidine-3-carboxylic acid compound
EP4077276A1 (en) *	2019-12-19	2022-10-26	Curia Spain S.A.U.	Process and intermediates for the preparation of upadacitinib
WO2021176473A1 (en) *	2020-03-05	2021-09-10	Mylan Laboratories Limited	A process for the preparation of upadacitinib and its intermediates
CN114206877B (en) *	2020-06-05	2024-04-19	苏州科睿思制药有限公司	Crystal form of Martinib and preparation method and application thereof
AU2021303629A1 (en) *	2020-07-08	2023-03-09	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of upadacitinib, preparation method therefor, and use thereof
WO2022044037A1 (en)	2020-08-24	2022-03-03	Mylan Laboratories Limited	An improved process for the preparation of upadacitinib intermediate
CN114621127A (en) *	2020-12-08	2022-06-14	苏州鹏旭医药科技有限公司	A kind of synthetic method of substituted dihydropyrrole
BR112023020826A2 (en) *	2021-04-07	2023-12-12	Abbvie Inc	UPADACITINIB COCRYSTALS
CN115724781A (en) *	2021-08-30	2023-03-03	凯特立斯（深圳）科技有限公司	Method for synthesizing empatinib key chiral intermediate
CN114380837B (en) *	2021-12-27	2023-06-30	上海邈金医药科技有限公司	Compound with Janus kinase inhibition activity, composition comprising compound and application of compound
US20250074912A1 (en) *	2022-01-06	2025-03-06	Msn Laboratories Private Limited, R&D Center	Improved process for the preparation of upadacitinib
WO2023138804A1 (en)	2022-01-20	2023-07-27	Renata Pharmaceutical (Ireland) Limited	Sustained release pharmaceutical composition of upadacitinib
CN114315679B (en) *	2022-01-21	2024-08-30	杭州新博思生物医药有限公司	Martinib chiral preparation method of intermediate
EP4215196A1 (en)	2022-01-24	2023-07-26	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2024075131A1 (en) *	2022-10-03	2024-04-11	Natco Pharma Limited	Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof
WO2024197127A1 (en)	2023-03-22	2024-09-26	Abbvie Inc.	Methods of treating pediatric patients with upadacitinib
CN121127242A (en)	2023-05-23	2025-12-12	艾伯维公司	Methods of treating vitiligo with utpatinib
US20250049789A1 (en)	2023-08-08	2025-02-13	Abbvie Inc.	Methods of treating alopecia araeta
CN117534678A (en) *	2023-11-08	2024-02-09	浙江宏元药业股份有限公司	New crystal form of Marpatinib and preparation method thereof
CN117285536B (en) *	2023-11-27	2024-02-20	中节能万润股份有限公司	Preparation method of Martinib intermediate
CN117285537B (en) *	2023-11-27	2024-02-06	中节能万润股份有限公司	Preparation method of Marpatinib
CN117285535B (en) *	2023-11-27	2024-02-02	中节能万润股份有限公司	Preparation method of Marpatinib intermediate and salified intermediate
CN117447481A (en) *	2023-12-23	2024-01-26	潍坊医学院	An amorphous substance of upatinib-pyroglutamate and its preparation method and application
WO2025149011A1 (en) *	2024-01-11	2025-07-17	浙江华海药业股份有限公司	Synthesis process for upadacitinib or hydrate thereof
CN118047785A (en) *	2024-03-07	2024-05-17	和鼎（南京）医药技术有限公司	Method for preparing Wu Pati Ni and intermediate thereof
KR20250146517A (en)	2024-04-01	2025-10-13	주식회사 파마코스텍	Alkyl-containing sulfonate compound of upadacitinib, and method for producing the same
WO2025221754A1 (en)	2024-04-17	2025-10-23	Abbvie Inc.	Upadacitinib for use in the treatment of giant cell arteritis
CN118370734B (en) *	2024-06-26	2024-10-01	山东则正医药技术有限公司	Martinib sustained release tablet and preparation method thereof

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB716327A (en)	1951-09-05	1954-10-06	Ici Ltd	New heterocyclic compounds
BE640616A (en)	1962-12-19
US3492397A (en)	1967-04-07	1970-01-27	Warner Lambert Pharmaceutical	Sustained release dosage in the pellet form and process thereof
US4060598A (en)	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en)	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
US3663559A (en)	1969-12-03	1972-05-16	Union Carbide Corp	Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4053474A (en)	1976-04-21	1977-10-11	E. R. Squibb & Sons, Inc.	Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US4173626A (en)	1978-12-11	1979-11-06	Merck & Co., Inc.	Sustained release indomethacin
US5605690A (en)	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
ATE195739T1 (en)	1989-10-20	2000-09-15	Kyowa Hakko Kogyo Kk	CONDENSED PURINE DERIVATIVES
WO1991010671A1 (en)	1990-01-11	1991-07-25	Isis Pharmaceuticals, Inc.	Compositions and methods for detecting and modulating rna activity and gene expression
US6262241B1 (en)	1990-08-13	2001-07-17	Isis Pharmaceuticals, Inc.	Compound for detecting and modulating RNA activity and gene expression
EP1681305A3 (en)	1991-03-18	2008-02-27	New York University	Monoclonal and chimeric antibodies specific for human tumor necrosis factor
CA2110942A1 (en)	1991-06-14	1992-12-23	Pharmacia & Upjohn Company Llc	Imidazo¬1,5-a\|quinoxalines
US5212310A (en)	1991-12-19	1993-05-18	Neurogen Corporation	Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en)	1992-04-30	1993-11-30	Neurogen Corporation	Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en)	1992-08-27	1994-04-26	Neurogen Corporation	Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
DE69303494T2 (en)	1992-11-13	1997-01-16	Idec Pharma Corp	THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
CN1118600A (en)	1993-02-26	1996-03-13	先灵公司	2-benzyl-polycyclic guanine derivatives and process for preparing them
US5736540A (en)	1993-07-29	1998-04-07	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en)	1993-07-29	1998-03-31	American Cyanamid Company	Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en)	1994-09-20	1996-08-20	Talley; John J.	Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (en)	1994-12-23	2000-10-27	Варнер-Ламберт Компани	Method for inhibiting epidermal growth factor receptor thyrosinekinase, nitrogen-containing tricyclic compounds and pharmaceutical composition for introducing epidermal growth factor receptor thyrosinekinase inhibitor like erb- b2, erb-b3 or erb-b4 and contraceptive composition
US5521173A (en)	1995-01-17	1996-05-28	American Home Products Corporation	Tricyclic benzazepine vasopressin antagonists
US5753648A (en)	1995-01-17	1998-05-19	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists
US5763137A (en)	1995-08-04	1998-06-09	Agfa-Gevaert, N.V.	Method for making a lithographic printing plate
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
FR2742676B1 (en)	1995-12-21	1998-02-06	Oreal	TRANSPARENT NANOEMULSION BASED ON SILICON SURFACTANTS AND USE IN COSMETICS OR DERMOPHARMACY
US5703244A (en)	1996-11-21	1997-12-30	Abbott Laboratories	Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds
DE69841972D1 (en)	1997-02-05	2010-12-09	Merck Sharp & Dohme	METHOD FOR CRYSTALLIZING A REVERSTRANSCRIPTASE INHIBITOR WHERE AN ANTI SOLVENT IS USED
EP1066286B1 (en)	1998-03-04	2009-04-29	Bristol-Myers Squibb Company	Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
JP2002524551A (en)	1998-09-14	2002-08-06	ワーナー−ランバート・カンパニー	Branched-chain alkylpyrrolidine-3-carboxylic acid
US6448253B1 (en)	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
DE19853665B4 (en)	1998-11-20	2005-06-30	Siemens Ag	Vehicle communication system and method for exchanging data in a motor vehicle
CO5271670A1 (en)	1999-10-29	2003-04-30	Pfizer Prod Inc	ANTIGONISTS OF THE CORTICITROPINE RELEASE FACTOR AND RELATED COMPOSITIONS
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
KR20030036678A (en)	2000-08-07	2003-05-09	뉴로젠 코포레이션	Heterocyclic compounds as ligands of the gabaa receptor
GB0115393D0 (en)	2001-06-23	2001-08-15	Aventis Pharma Ltd	Chemical compounds
GB0124299D0 (en)	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
MXPA04008680A (en)	2002-02-19	2004-12-06	Pharmacia Italia Spa	Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents.
US20030181488A1 (en)	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
CN1713910A (en)	2002-10-09	2005-12-28	西奥斯股份有限公司	Azaindole derivatives as inhibitors of p38 kinase
JP2006516561A (en)	2003-01-17	2006-07-06	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	2-Aminopyridine substituted heterocycles as inhibitors of cell proliferation
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
AR044510A1 (en)	2003-04-14	2005-09-14	Merck & Co Inc	PROCEDURE AND INTERMEDIATES TO PREPARE CARBOXILIC ACIDS OF PIRROLIDINE
US7176214B2 (en)	2003-05-21	2007-02-13	Bristol-Myers Squibb Company	Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7592466B2 (en) *	2003-10-09	2009-09-22	Abbott Laboratories	Ureas having antiangiogenic activity
ES2318343T3 (en)	2003-10-09	2009-05-01	Abbott Laboratories	DERIVATIVES OF PIRROLIDINIL UREA AS INHIBITORS OF ANGIOGENESIS ..
JP2007537296A (en)	2004-05-14	2007-12-20	アボット・ラボラトリーズ	Kinase inhibitors as therapeutic agents
PE20060526A1 (en)	2004-06-15	2006-07-13	Schering Corp	TRICYCLE COMPOUNDS AS ANTAGONISTS OF MGLUR1
CN1968684A (en)	2004-06-17	2007-05-23	森林实验室公司	Modified release formulation of memantine
ATE455777T1 (en)	2004-07-23	2010-02-15	Medicines Co Leipzig Gmbh	SUBSTITUTED PYRIDOÄ3',2':4,5ÜTHIENOÄ3,2-DÜPYRIMIDINES AND PYRIDOÄ3',2':4,5ÜFUROÄ3,2-DÜ-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE
US7626021B2 (en)	2004-07-27	2009-12-01	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
AU2005269387A1 (en)	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
CN100381175C (en)	2004-10-09	2008-04-16	山西中医学院	Microemulsion preparation and preparation method thereof
EP1814882A1 (en)	2004-11-22	2007-08-08	Vertex Pharmaceuticals Incorporated	Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
JP5270167B2 (en)	2004-12-21	2013-08-21	アリーナファーマシューティカルズ，インコーポレイテッド	Crystalline form of (R) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
US7947694B2 (en)	2005-01-14	2011-05-24	Janssen Pharmaceutica Nv	Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors
WO2006074985A1 (en)	2005-01-14	2006-07-20	Janssen Pharmaceutica N.V.	5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US20060183758A1 (en) *	2005-02-17	2006-08-17	Cb Research And Development, Inc.	Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
JP2008538119A (en)	2005-04-01	2008-10-09	コーリーファーマシューティカルグループ，インコーポレーテッド	Pyrazolo [3,4-c] quinolines, pyrazolo [3,4-c] naphthyridines, analogs thereof, and methods
US7737279B2 (en)	2005-05-10	2010-06-15	Bristol-Myers Squibb Company	1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en)	2005-05-12	2009-09-22	Cytopia Research Pty Ltd	Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EP1910358A2 (en)	2005-07-14	2008-04-16	Astellas Pharma Inc.	Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en)	2005-07-14	2010-11-17	Astellas Pharma Inc.	Heterocyclic Janus kinase 3 inhibitors
EP1919924A2 (en)	2005-08-16	2008-05-14	Irm, Llc	Compounds and compositions as protein kinase inhibitors
BRPI0617534A2 (en) *	2005-09-23	2011-07-26	Memory Pharm Corp	COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR THE SELECTIVE ACTIVATION / STIMULATION OF A-7 NICOTINIC RECEPTORS IN A PATIENT, METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A PSYCHOTIC DISEASE, A DISEASES AND A NEURODEGENERATIVE DISEASE. OR A CONDITION OF DEGENERATION OF MEMORY AND / OR COGNITION, METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM DEMENTIA AND / OR ANOTHER CONDITION WITH LOSS OF MEMORY, METHOD FOR TREATING A PATIENT SUFFERING DEGENERATION OF DEATH MEMORY SOFT COGNITIVE DEGENERATION DUE TO AGING, ALZHEIMER EVIL, SCHIZOPHRENIA, PARKINSON EVIL, HUNTINGTON EVIL, PICK EVIL, CREUTZFELDT-JAKOB EVIL, DEPRESSION, AGING, SICKNESS, HARMONY, HARMONY, ACCIDENT, HEALTH, HEALTH MULTIINFARTO DEMENTIA, HIV AND / OR CARDIOVASCULAR DISEASE, METHOD FOR TREATING AND / OR PREVENTING DEMENTIA IN A PATIENT WITH ALZHEIMER'S EVIL , METHOD FOR THE TREATMENT OF A PATIENT FOR THE WITHDRAWAL OF ALCOHOL OR FOR THE TREATMENT OF A PATIENT WITH ANTI-TOXIC THERAPY, METHOD FOR THE TREATMENT OF A PATIENT TO CONFIRM NEUROPROTECTION AGAINST DAMAGE ASSOCIATED WITH CEREBRAL EARLY ACCIDENT ACCIDENTS GLUTAMATE, METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM NICOTIN ADDICTION, PAIN, TIME DIFFERENCE, OBESITY AND / OR DIABETES, METHOD OF INDUCING A PATIENT TO STOP SMOKING, METHOD FOR TREATING A PATIENT WHO SUFFERS SOFT COGNITIVE DEGENERATION (MCI), VASCULAR DEMENTIA (VAD), COGNITIVE DECLINATION ASSOCIATED WITH AGE (AACD), AMNESIA ASSOCIATED WITH OPEN HEART SURGERY, CARDIAC APPRECIATION, GENERAL ANESTHESIA, DEDEYOUS EXPERTISE (DEODOUS EXPERIENCE, DEDEYOUS EXPERIENCE, .)
WO2007035935A1 (en)	2005-09-23	2007-03-29	Coley Pharmaceutical Group, Inc.	METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
US8106066B2 (en) *	2005-09-23	2012-01-31	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
EP1954290B1 (en)	2005-11-22	2012-07-25	Merck Sharp & Dohme Corp.	Tricyclic compounds useful as inhibitors of kinases
TW201307354A (en)	2005-12-29	2013-02-16	Abbott Lab	Protein kinase inhibitors
CN101460461B (en) *	2006-04-03	2012-10-03	弗·哈夫曼-拉罗切有限公司	Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids
JP5386350B2 (en)	2006-05-31	2014-01-15	タケダカリフォルニアインコーポレイテッド	Indazole and isoindole derivatives as glucokinase activators
US8063225B2 (en)	2006-08-14	2011-11-22	Chembridge Corporation	Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
AR062320A1 (en)	2006-08-14	2008-10-29	Boehringer Ingelheim Int	FLIBANSERIN FORMULATIONS AND METHOD TO MANUFACTURE THEM
WO2008063287A2 (en)	2006-10-06	2008-05-29	Abbott Laboratories	Novel imidazothiazoles and imidazoxazoles
HRP20150642T1 (en)	2006-12-22	2015-08-14	Astex Therapeutics Limited	BIKE HETEROCYCLIC SUBSTANCES AS FGFR INHIBITORS
KR20090106604A (en)	2007-01-12	2009-10-09	아스텔라스세이야쿠 가부시키가이샤	Condensed pyridine compounds
CN101230059B (en) *	2007-01-23	2011-08-17	上海恒瑞医药有限公司	Bicyclic aza-alkane derivatives, their preparation method and their use in medicine
EP2108019A2 (en)	2007-01-30	2009-10-14	Biogen Idec MA, Inc.	1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
WO2008112695A2 (en)	2007-03-12	2008-09-18	Irm Llc	Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7834024B2 (en)	2007-03-26	2010-11-16	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
US7723343B2 (en)	2007-03-30	2010-05-25	King Pharmaceuticals Research And Development, Inc.	Adenosine A2A receptor antagonists
AU2008234822A1 (en)	2007-04-02	2008-10-09	Palau Pharma, S. A.	Pyrrolopyrimidine derivatives as JAK3 inhibitors
KR101443943B1 (en)	2007-05-07	2014-10-07	에보니크 룀 게엠베하	Solid dosage forms comprising enteric coatings with accelerated drug release
MY147330A (en)	2007-05-11	2012-11-30	Pfizer	Amino-heterocyclic compounds
EP2170337A4 (en)	2007-06-28	2013-12-18	Abbvie Inc	Novel triazolopyridazines
US20090022789A1 (en)	2007-07-18	2009-01-22	Supernus Pharmaceuticals, Inc.	Enhanced formulations of lamotrigine
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
WO2009085310A1 (en)	2007-12-26	2009-07-09	Teva Pharmaceutical Industries Ltd.	Extended-release pharmaceutical compositions containing zolpidem
CN101952294B (en) *	2008-02-25	2014-11-26	霍夫曼-拉罗奇有限公司	Pyrrolopyrazine kinase inhibitors
EP2247595B1 (en)	2008-02-25	2011-07-20	F. Hoffmann-La Roche AG	Pyrrolopyrazine kinase inhibitors
PL2247592T3 (en) *	2008-02-25	2012-01-31	Hoffmann La Roche	Pyrrolopyrazine kinase inhibitors
WO2009108827A1 (en)	2008-02-29	2009-09-03	Wyeth	Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
US20120276206A1 (en)	2008-03-28	2012-11-01	Boehringer Ingelheim International Gmbh	Method for manufacturing acid pellets
SI2299821T1 (en)	2008-06-10	2016-03-31	Abbvie Inc.	Tricyclic compounds
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
JP2011526931A (en)	2008-07-03	2011-10-20	エグゼリクシス，インコーポレイテッド	CDK modulator
CN101638423B (en) *	2008-07-29	2012-09-05	常州高新技术产业开发区三维工业技术研究所有限公司	Phloridzin derivative as well as preparation method and application thereof
BRPI1008906B1 (en)	2009-02-24	2019-10-15	Merck Sharp & Dohme Corp.	COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
WO2010117796A2 (en)	2009-03-30	2010-10-14	Codexis, Inc.	Processes for the preparation of alpha-chloroketones from carboxylic acids
AU2010237859A1 (en)	2009-04-14	2011-11-03	Astellas Pharma Inc.	Fused pyrrolopyridine derivative
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
US8367689B2 (en)	2009-05-06	2013-02-05	Portola Pharmaceuticals, Inc.	Inhibitors of JAK
CN101904814A (en)	2009-06-04	2010-12-08	上海恒瑞医药有限公司	Preparation method of drug loaded emulsion
FR2947276B1 (en)	2009-06-24	2012-10-26	Seppic Sa	COSMETIC COMPOSITION BASED ON ION EXCHANGE RESINS LOADED WITH LIPOAMINOACIDES
US8361962B2 (en)	2009-07-27	2013-01-29	Roche Palo Alto Llc	Tricyclic inhibitors of JAK
CA2769760A1 (en)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Multi-layered, multiple unit pharmaceutical compositions
US8785639B2 (en)	2009-12-01	2014-07-22	Abbvie Inc.	Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
PL2506716T3 (en)	2009-12-01	2017-10-31	Abbvie Inc	Novel tricyclic compounds
AU2011224484A1 (en)	2010-03-10	2012-09-27	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US20130034604A1 (en)	2010-05-14	2013-02-07	Alembic Pharmaceuticals Limited	Extended release formulations of desvenlafaxine base
CA2802067A1 (en)	2010-06-09	2011-12-15	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a protein
US8637529B2 (en)	2010-06-11	2014-01-28	AbbYie Inc.	Pyrazolo[3,4-d]pyrimidine compounds
WO2012041814A1 (en)	2010-09-27	2012-04-05	Abbott Gmbh & Co. Kg	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9011912B2 (en)	2010-10-07	2015-04-21	Abon Pharmaceuticals, Llc	Extended-release oral dosage forms for poorly soluble amine drugs
US20120231083A1 (en)	2010-11-18	2012-09-13	The Board Of Trustees Of The University Of Illinois	Sustained release cannabinoid medicaments
WO2012149280A2 (en)	2011-04-29	2012-11-01	Abbott Laboratories	Novel tricyclic compounds
WO2013043826A1 (en)	2011-09-21	2013-03-28	Abbvie Inc.	Tricyclic compounds useful as protein kinase inhibitors
FR2991171B1 (en)	2012-06-01	2014-05-23	Galderma Res & Dev	PROCESS FOR THE PREPARATION OF A DERMATOLOGICAL COMPOSITION COMPRISING OLEOSOMES
WO2014004863A2 (en)	2012-06-27	2014-01-03	Alzheimer's Institute Of America, Inc.	Compounds, compositions, and therapeutic uses thereof
SI2874630T1 (en)	2012-07-20	2019-04-30	Zoetis Services Llc	Dosing regimen for janus kinase (jak) inhibitors
HUE040434T2 (en)	2013-02-21	2019-03-28	Pfizer	Solid forms of selective CDK4 / 6 inhibitor
MY177476A (en)	2013-02-22	2020-09-16	Pfizer	Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
CN105209469A (en)	2013-03-15	2015-12-30	全球血液疗法股份有限公司	Compounds and uses thereof for the modulation of hemoglobin
JP6041823B2 (en)	2013-03-16	2016-12-14	ファイザー・インク	Tofacitinib oral sustained release dosage form
WO2014174073A1 (en)	2013-04-26	2014-10-30	Sandoz Ag	Sustained release formulations of tofacitinib
AU2014339897A1 (en)	2013-10-24	2016-04-21	Abbvie Inc.	JAK1 selective inhibitor and uses thereof
JP2017529334A (en)	2014-08-27	2017-10-05	アッヴィ・インコーポレイテッド	Topical formulation
CA2987867C (en)	2015-06-09	2023-06-27	Capsugel Belgium Nv	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP2018527337A (en)	2015-08-13	2018-09-20	ファイザー・インク	Bicyclic fused heteroaryl or aryl compounds
WO2017033093A1 (en)	2015-08-27	2017-03-02	Pfizer Inc.	Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20170129902A1 (en)	2015-10-16	2017-05-11	Abbvie Inc.	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
PL3383363T3 (en)	2015-11-30	2021-05-31	Anacor Pharmaceuticals, Inc.	TOPICAL PHARMACEUTICAL PREPARATIONS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH INFLAMMATION
WO2017126488A1 (en)	2016-01-18	2017-07-27	持田製薬株式会社	Psoriasis treatment composition and treatment method
WO2017143014A1 (en)	2016-02-16	2017-08-24	Brian Kim	Jak inhibitors and uses thereof
MY205229A (en)	2016-07-06	2024-10-08	Durect Corp	Oral dosage form with drug composition, barrier layer and drug layer
US11564922B2 (en)	2017-03-09	2023-01-31	Abbvie Inc.	Methods of treating crohn's disease and ulcerative colitis
CN110392572A (en)	2017-03-09	2019-10-29	艾伯维公司	Treatments for Crohn's disease and ulcerative colitis
EP4463161A2 (en)	2022-01-13	2024-11-20	Abbvie Inc.	Method of administering upadacitinib to avoid adverse drug interactions and effects

2016
- 2016-10-17 US US15/295,561 patent/US20170129902A1/en not_active Abandoned
- 2016-10-17 JP JP2018517576A patent/JP6770775B2/en active Active
- 2016-10-17 SG SG10201913990RA patent/SG10201913990RA/en unknown
- 2016-10-17 AU AU2016340167A patent/AU2016340167B2/en active Active
- 2016-10-17 CN CN202510619339.8A patent/CN120289468A/en active Pending
- 2016-10-17 SG SG11201802990RA patent/SG11201802990RA/en unknown
- 2016-10-17 MX MX2018004605A patent/MX387822B/en unknown
- 2016-10-17 RU RU2018117889A patent/RU2018117889A/en unknown
- 2016-10-17 CA CA3123260A patent/CA3123260C/en active Active
- 2016-10-17 WO PCT/US2016/057372 patent/WO2017066775A1/en not_active Ceased
- 2016-10-17 SG SG10201913989QA patent/SG10201913989QA/en unknown
- 2016-10-17 BR BR122022024925-6A patent/BR122022024925B1/en active IP Right Grant
- 2016-10-17 EP EP25205009.1A patent/EP4647129A2/en active Pending
- 2016-10-17 CN CN202211671688.7A patent/CN116284011A/en active Pending
- 2016-10-17 SG SG10201913993QA patent/SG10201913993QA/en unknown
- 2016-10-17 CA CA3257305A patent/CA3257305C/en active Active
- 2016-10-17 CA CA3252702A patent/CA3252702A1/en active Pending
- 2016-10-17 IL IL314468A patent/IL314468A/en unknown
- 2016-10-17 CN CN202510619337.9A patent/CN120478294A/en active Pending
- 2016-10-17 CN CN201680070259.0A patent/CN108368121B/en active Active
- 2016-10-17 CA CA3002220A patent/CA3002220C/en active Active
- 2016-10-17 EP EP23151673.3A patent/EP4219503A1/en active Pending
- 2016-10-17 CN CN202510619817.5A patent/CN120483986A/en active Pending
- 2016-10-17 CA CA3252663A patent/CA3252663A1/en active Pending
- 2016-10-17 KR KR1020187013644A patent/KR102753815B1/en active Active
- 2016-10-17 SG SG10201913997WA patent/SG10201913997WA/en unknown
- 2016-10-17 SG SG10201913999PA patent/SG10201913999PA/en unknown
- 2016-10-17 CN CN202211671776.7A patent/CN116270645A/en active Pending
- 2016-10-17 SG SG10201913986YA patent/SG10201913986YA/en unknown
- 2016-10-17 CA CA3251507A patent/CA3251507A1/en active Pending
- 2016-10-17 CA CA3254966A patent/CA3254966A1/en active Pending
- 2016-10-17 EP EP16788358.6A patent/EP3362455A1/en not_active Withdrawn
- 2016-10-17 CA CA3257291A patent/CA3257291A1/en active Pending
- 2016-10-17 KR KR1020257000604A patent/KR20250010141A/en active Pending
- 2016-10-17 CN CN202211671778.6A patent/CN116270646A/en active Pending
- 2016-10-17 SG SG10201913987UA patent/SG10201913987UA/en unknown
2017
- 2017-08-21 US US15/682,457 patent/US9879019B2/en active Active
- 2017-08-21 US US15/682,451 patent/US9879018B2/en active Active
- 2017-11-03 US US15/803,538 patent/US9951080B2/en active Active
- 2017-12-29 US US15/857,892 patent/US9963459B1/en active Active
2018
- 2018-02-07 US US15/891,306 patent/US10017517B2/en active Active
- 2018-02-07 US US15/891,012 patent/US20190023714A1/en not_active Abandoned
- 2018-02-28 US US15/908,347 patent/US10344036B2/en active Active
- 2018-04-04 US US15/945,225 patent/US10202393B2/en active Active
- 2018-04-04 US US15/945,231 patent/US10202394B2/en active Active
- 2018-04-11 IL IL258654A patent/IL258654A/en unknown
- 2018-04-13 MX MX2021013812A patent/MX2021013812A/en unknown
2019
- 2019-06-26 US US16/453,684 patent/US10519164B2/en active Active
- 2019-07-01 US US16/458,622 patent/US10597400B2/en active Active
- 2019-10-17 US US16/656,237 patent/US20200291040A1/en not_active Abandoned
2020
- 2020-02-11 US US16/787,251 patent/US10730883B2/en active Active
- 2020-06-18 US US16/905,667 patent/US10981923B2/en active Active
- 2020-08-03 US US16/983,701 patent/US10981924B2/en active Active
- 2020-09-24 JP JP2020159855A patent/JP7358317B2/en active Active
2021
- 2021-02-24 US US17/184,194 patent/US20210363149A1/en not_active Abandoned
- 2021-04-14 US US17/230,418 patent/US11198697B1/en active Active
- 2021-04-14 US US17/230,288 patent/US11186584B2/en active Active
- 2021-05-28 IL IL283531A patent/IL283531A/en unknown
- 2021-09-24 AU AU2021236570A patent/AU2021236570B2/en active Active
2022
- 2022-05-13 JP JP2022079226A patent/JP2022107001A/en active Pending
- 2022-05-27 US US17/827,054 patent/US11535624B2/en active Active
- 2022-09-23 US US17/951,332 patent/US11680069B2/en active Active
- 2022-09-23 US US17/951,334 patent/US11661425B2/en active Active
2023
- 2023-01-06 US US18/094,263 patent/US11773105B2/en active Active
- 2023-01-06 US US18/094,266 patent/US11718627B2/en active Active
- 2023-02-27 US US18/174,738 patent/US11780847B1/en active Active
- 2023-02-27 US US18/174,736 patent/US11787815B1/en active Active
- 2023-03-01 US US18/176,647 patent/US11795175B2/en active Active
- 2023-06-02 US US18/328,325 patent/US12116373B2/en active Active
- 2023-06-02 US US18/328,350 patent/US12134621B2/en active Active
- 2023-06-06 US US18/329,980 patent/US12091415B2/en active Active
- 2023-06-06 US US18/329,986 patent/US12110297B2/en active Active
- 2023-06-06 US US18/329,988 patent/US12103933B2/en active Active
- 2023-06-12 JP JP2023096042A patent/JP2023113917A/en active Pending
- 2023-07-28 US US18/361,582 patent/US20230374027A1/en not_active Abandoned
- 2023-09-18 US US18/369,272 patent/US12110298B2/en active Active
- 2023-10-19 AU AU2023251492A patent/AU2023251492B2/en active Active
- 2023-12-05 US US18/530,071 patent/US20240166657A1/en not_active Abandoned
- 2023-12-05 US US18/530,077 patent/US12077545B2/en active Active
2024
- 2024-03-18 JP JP2024041977A patent/JP2024073591A/en active Pending
- 2024-06-05 US US18/734,105 patent/US20240317770A1/en not_active Abandoned
- 2024-07-17 US US18/776,040 patent/US20240376115A1/en not_active Abandoned
2025
- 2025-01-21 US US19/032,963 patent/US20250163071A1/en not_active Abandoned
- 2025-07-01 AU AU2025205010A patent/AU2025205010A1/en active Pending
- 2025-08-08 JP JP2025133176A patent/JP2025166112A/en active Pending
- 2025-08-08 JP JP2025133177A patent/JP2025166113A/en active Pending
- 2025-10-23 AU AU2025256155A patent/AU2025256155A1/en active Pending

Also Published As

Publication number	Publication date
CN116284011A (en)	2023-06-23
CA3252663A1 (en)	2025-04-23
US12077545B2 (en)	2024-09-03
US20230203049A1 (en)	2023-06-29
US9951080B2 (en)	2018-04-24
SG10201913993QA (en)	2020-03-30
IL283531A (en)	2021-07-29
JP2024073591A (en)	2024-05-29
AU2025256155A1 (en)	2025-11-13
US20190315761A1 (en)	2019-10-17
JP2023113917A (en)	2023-08-16
US20240174682A1 (en)	2024-05-30
KR20250010141A (en)	2025-01-20
KR102753815B1 (en)	2025-01-14
US20210363149A1 (en)	2021-11-25
US12134621B2 (en)	2024-11-05
US20170342083A1 (en)	2017-11-30
US20240034740A1 (en)	2024-02-01
JP2022107001A (en)	2022-07-20
CA3257291A1 (en)	2025-04-07
US10730883B2 (en)	2020-08-04
US11661425B2 (en)	2023-05-30
MX2021013812A (en)	2021-12-14
US20230374027A1 (en)	2023-11-23
US9879018B2 (en)	2018-01-30
US20180222914A1 (en)	2018-08-09
CA3252702A1 (en)	2025-07-08
US20230331735A1 (en)	2023-10-19
US10597400B2 (en)	2020-03-24
CN116270646A (en)	2023-06-23
US10202393B2 (en)	2019-02-12
US10344036B2 (en)	2019-07-09
HK1263380A1 (en)	2020-05-29
US12110297B2 (en)	2024-10-08
SG11201802990RA (en)	2018-05-30
JP2019501865A (en)	2019-01-24
US11795175B2 (en)	2023-10-24
US11718627B2 (en)	2023-08-08
AU2023251492A1 (en)	2023-11-09
US10519164B2 (en)	2019-12-31
US20180186805A1 (en)	2018-07-05
US20240166657A1 (en)	2024-05-23
SG10201913999PA (en)	2020-03-30
CA3257305C (en)	2025-11-18
BR112018007677A2 (en)	2018-11-06
US12110298B2 (en)	2024-10-08
RU2018117889A (en)	2019-11-20
US20210309667A1 (en)	2021-10-07
US20200181158A1 (en)	2020-06-11
AU2023251492B2 (en)	2025-04-03
JP7358317B2 (en)	2023-10-10
US20180222913A1 (en)	2018-08-09
US20230057084A1 (en)	2023-02-23
US20180141955A1 (en)	2018-05-24
CA3257305A1 (en)	2025-06-12
CA3002220C (en)	2021-07-20
CN108368121B (en)	2023-01-13
CA3123260A1 (en)	2017-04-20
AU2025205010A1 (en)	2025-07-24
CA3251507A1 (en)	2025-05-21
US10981923B2 (en)	2021-04-20
US20220298165A1 (en)	2022-09-22
CN120478294A (en)	2025-08-15
EP3362455A1 (en)	2018-08-22
US9879019B2 (en)	2018-01-30
US20200291040A1 (en)	2020-09-17
US9963459B1 (en)	2018-05-08
JP2025166112A (en)	2025-11-05
CA3002220A1 (en)	2017-04-20
US20230219968A1 (en)	2023-07-13
MX2018004605A (en)	2018-11-29
US11680069B2 (en)	2023-06-20
EP4219503A1 (en)	2023-08-02
US11780847B1 (en)	2023-10-10
US20200361949A1 (en)	2020-11-19
US11198697B1 (en)	2021-12-14
US12116373B2 (en)	2024-10-15
US20170129902A1 (en)	2017-05-11
IL258654A (en)	2018-06-28
SG10201913989QA (en)	2020-03-30
US20230348481A1 (en)	2023-11-02
SG10201913997WA (en)	2020-03-30
US20170362247A1 (en)	2017-12-21
AU2021236570B2 (en)	2023-11-02
CA3254966A1 (en)	2025-04-12
US20240317770A1 (en)	2024-09-26
AU2016340167B2 (en)	2021-06-24
US11773105B2 (en)	2023-10-03
US10017517B2 (en)	2018-07-10
US20240376115A1 (en)	2024-11-14
US20180162865A1 (en)	2018-06-14
AU2016340167A8 (en)	2018-05-10
CN108368121A (en)	2018-08-03
US12091415B2 (en)	2024-09-17
US12103933B2 (en)	2024-10-01
US20190023714A1 (en)	2019-01-24
US20230322794A1 (en)	2023-10-12
US20230058001A1 (en)	2023-02-23
US20230312593A1 (en)	2023-10-05
CN120483986A (en)	2025-08-15
JP6770775B2 (en)	2020-10-21
RU2018117889A3 (en)	2020-08-12
US10981924B2 (en)	2021-04-20
US20230303582A1 (en)	2023-09-28
CA3123260C (en)	2025-03-11
WO2017066775A1 (en)	2017-04-20
CN116270645A (en)	2023-06-23
SG10201913990RA (en)	2020-03-30
BR122022024925B1 (en)	2023-11-28
US10202394B2 (en)	2019-02-12
JP2025166113A (en)	2025-11-05
EP4647129A2 (en)	2025-11-12
US20240010656A1 (en)	2024-01-11
US20190322677A1 (en)	2019-10-24
MX387822B (en)	2025-03-19
AU2016340167A1 (en)	2018-04-26
US11186584B2 (en)	2021-11-30
KR20180081523A (en)	2018-07-16
SG10201913986YA (en)	2020-03-30
US11787815B1 (en)	2023-10-17
JP2021020902A (en)	2021-02-18
US20180057502A1 (en)	2018-03-01
US20200317682A1 (en)	2020-10-08
US20230183257A1 (en)	2023-06-15
US20230312595A1 (en)	2023-10-05
AU2021236570A1 (en)	2021-10-28
US11535624B2 (en)	2022-12-27
IL314468A (en)	2024-09-01
US20250163071A1 (en)	2025-05-22
CN120289468A (en)	2025-07-11

Publication	Publication Date	Title
IL283531A (en)	2021-07-29	Processes for the preparation of (3s,4r)-3-ethyl-4-(3h- imidiazo[1,2-a]pyrrolo[2, 3-e]-pyrazin-8-yl)-n-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
IL268737A (en)	2019-10-31	Processes for the preparation of benzodiazepine derivatives
IL266170A (en)	2019-06-30	Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
IL270909A (en)	2020-01-30	Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
EP3468973A4 (en)	2020-02-26	Solid forms of venetoclax and processes for the preparation of venetoclax
IL250280B (en)	2021-02-28	Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds, derivatives thereof and pharmaceutical compositions comprising them
EP3250572A4 (en)	2018-06-20	Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
IL262257B (en)	2020-11-30	1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
HUE057549T2 (en)	2022-05-28	Imidazo [1,2-a] pyrimidine derivatives, process for their preparation and their use
IL251107B (en)	2022-05-01	Derivatives of-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one, pharmaceutical composition comprising them and their use in treating cns sisorderes.
EP3120994A4 (en)	2017-05-17	Hollow structural body and component for vehicles
GB201802644D0 (en)	2018-04-04	Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
GB201522532D0 (en)	2016-02-03	Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
ZA201902828B (en)	2022-05-25	Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
HK1260882A1 (en)	2019-12-20	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CA3254963A1 (en)	2025-10-30	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
HK40095836A (en)	2024-02-09	Processes for the preparation of imidazo[1,2-a]pyrrolo[2,3-e]-pyrazine compounds and solid state forms thereof
HK40095827A (en)	2024-02-09	Processes for the preparation of imidazo[1,2-a]pyrrolo[2,3-e]pyrazine compounds and solid state forms thereof
HK40095835A (en)	2024-02-09	Process for the preparation of imidazo[1,2- a]pyrrolo[2,3-e]pyrazine compound and solid state forms thereof
SG11202001266XA (en)	2020-03-30	Process for the preparation of low haze and color stable styrenic polymers
IL253427A0 (en)	2017-09-28	Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
HK1238643A1 (en)	2018-05-04	Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
IL274560A (en)	2020-06-30	Process for the preparation of raltegravir
HK40022783A (en)	2020-11-20	Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
HK40012574A (en)	2020-07-24	Liquid allergen compositions and methods for making the same